UBS (Lux) Equity Fund - Sustainable Health Transformation (USD) (EUR hedged) P-acc

Reference Data

ISIN LU2402148576
Valor Number 114551789
Bloomberg Global ID UBHPUAC LX
Fund Name UBS (Lux) Equity Fund - Sustainable Health Transformation (USD) (EUR hedged) P-acc
Fund Provider UBS Asset Management Switzerland AG 8098 Zürich, Schweiz
E-Mail: ubs-am-wholesale-switzerland@ubs.com
Web: www.ubs.com/fonds
Fund Provider UBS Asset Management Switzerland AG
Representative in Switzerland UBS Fund Management (Switzerland) AG
Basel
Phone: +41 61 288 49 10
Distributor(s) UBS Global Asset Management
Basel
Phone: +41 61 288 20 20
Asset Class Equities
EFC Category Equity Health Care
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The Fund’s investment objective consists in generating strong capital appreciation with a reasonable level of income, while giving due consideration to capital security and the liquidity of the Fund’s assets. This sub-fund is a Sustainability Focus Fund. This sub-fund promotes environmental and/or social characteristics and complies with Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector (“SFDR”). This actively managed sub-fund invests at least two thirds of its assets worldwide in shares or other equity interests of companies in developed or emerging markets, which mainly promote United Nations Sustainable Development Goal 3 (Good Health and Well-Being). The focus is on companies that capitalise on healthcare transformation.
Peculiarities

Fund Prices

Current Price * 94.95 EUR 20.12.2024
Previous Price * 93.90 EUR 19.12.2024
52 Week High * 108.46 EUR 30.08.2024
52 Week Low * 92.11 EUR 17.04.2024
NAV * 94.95 EUR 20.12.2024
Issue Price * 94.95 EUR 20.12.2024
Redemption Price * 94.95 EUR 20.12.2024
Closing Price *
Indicative Minimum Price
Fund Assets *** 243,314,814
Unit/Share Assets *** 6,846,200
Trading Information SIX

Performance

YTD Performance -1.35% 29.12.2023
20.12.2024
YTD Performance (in CHF) -1.00% 29.12.2023
20.12.2024
1 month -2.31% 20.11.2024
20.12.2024
3 months -9.97% 20.09.2024
20.12.2024
6 months -4.65% 20.06.2024
20.12.2024
1 year +2.11% 20.12.2023
20.12.2024
2 years +5.90% 20.12.2022
20.12.2024
3 years -5.86% 20.12.2021
20.12.2024
5 years -5.05% 24.11.2021
20.12.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

UnitedHealth Group Inc 9.85%
Eli Lilly and Co 9.50%
AstraZeneca PLC 5.77%
Intuitive Surgical Inc 5.36%
Koninklijke Philips NV 4.88%
Sandoz Group AG Registered Shares 4.58%
Chugai Pharmaceutical Co Ltd 4.15%
Novartis AG Registered Shares 4.05%
Bristol-Myers Squibb Co 4.02%
Alcon Inc 3.98%
Last data update 30.11.2024

Cost / Risk

TER 1.84%
TER date 30.11.2023
Performance Fee *** 0.00%
PTR
Max. Management Fee *** 1.41%
Ongoing Charges *** 1.84%
SRRI ***
SRRI date ***

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Created with Highstock 2.1.1063.2% United States14.1% Switzerland8.8% United Kingdom5.0% Netherlands4.2% Japan1.7% China1.6% Denmark1.5% Germany

Stock Sectors ***

Created with Highstock 2.1.10100.0% Healthcare

Bond Sectors ***

Created with Highstock 2.1.1089.4% Derivative10.6% Cash & Equivalents

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)